Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 21, 2026, 2:38 PM EDT
Terminated Phase 3 Interventional

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

NCT00812240
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Masitinib, Imatinib
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
7
States / cities
Orlando, Florida • Atlanta, Georgia • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

NCT07722611
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

NCT03198507
View directory record Official record
Conditions
Helicobacter Pylori Infection, Dyspepsia
Interventions
RHB-105, Active Comparator
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
55
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease

NCT00646204
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Memantine, placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Helping Those With Mental Illness Quit Smoking

NCT01783912
View directory record Official record
Conditions
Smoking, Nicotine Dependence, Mental Disorders
Interventions
Cognitive / Motivational Individual Sessions, Attention Control Individual Sessions, Nicotine Patch, Group Curriculum
Behavioral · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional

Comparative-effectiveness of a Healthy Lifestyle and Asthma Management Program, In-person vs. ONline

NCT06432790
View directory record Official record
Conditions
Overweight, Childhood, Obesity, Childhood, Asthma in Children
Interventions
CHAMPION
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

NCT01793610
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl, Psychotherapy
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

NCT00093886
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, nitroglycerin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Heart Failure Insomnia Treatment Study

NCT03636880
View directory record Official record
Conditions
Heart Failure, Cardiac Failure, Congestive Heart Failure, Insomnia, Sleep Disorder, Sleep Initiation and Maintenance Disorders, Disorders of Initiating and Maintaining Sleep, Anxiety, Depression
Interventions
Brief treatment for Insomnia, Sleep Monitoring
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

NCT00995449
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
KB003, Placebo Comparator
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Stanford, California • Westlake Village, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single-Session Intervention Targeting Self-Injurious Behavior in Adolescents

NCT04498143
View directory record Official record
Conditions
Nonsuicidal Self Injury, Self Hatred, Suicidal Thoughts, Suicide Attempts
Interventions
Project SAVE ("Stop Adolescent Violence Everywhere") SSI, Active Comparator: Supportive Therapy ("Share Your Feelings") SSI
Other
Lead sponsor
University of Denver
Other
Eligibility
13 Years to 16 Years
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Heated Vest for Persons With Spinal Cord Injury

NCT03662308
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Heated Vest, Non-Heated Vest
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 68 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Not yet recruiting Phase 2 Interventional

Daridorexant for People With Insomnia and Alcohol Use Disorder Study

NCT07701928
View directory record Official record
Conditions
Alcohol Use Disorder, Insomnia
Interventions
Daridorexant, Placebo, Brief Counseling, MEMS and Medication Accounting, Contingency Management for Medication Adherence
Drug · Behavioral · Device
Lead sponsor
Sterling McPherson
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Investigation and Modulation of the Mu-opioid Mechanisms in TMD (in Vivo)

NCT03724032
View directory record Official record
Conditions
Temporomandibular Disorder
Interventions
HD-tDCS*, Sham HD-tDCS*
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

NCT00443755
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
Interventions
metformin, pioglitazone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

NCT02827500
View directory record Official record
Conditions
Heart Failure
Interventions
ivabradine, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Aurora, Colorado • Fort Lauderdale, Florida • Athens, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 21, 2026, 2:38 PM EDT